MaxCyte, Inc (MXCT): רווח נקי למניה (EPS TTM)

MaxCyte, Inc. (MXCT) operates within a secure legal framework in the US and EU, supplying equipment to pharmaceutical behemoths. The distribution of net income per share TTM helps assess the quality of the asset, where the value -0.33 expresses the state of the metric. MaxCyte, Inc. (MXCT) dominates the electroporation sector due to its patents and FDA certification, although it faces pressure from major providers of integrated laboratory systems.

Business vulnerability to market shocks is mitigated through the analysis of net income per share, which allows for an assessment of real capital generation efficiency without accounting for equity dilution. The high authority of MaxCyte, Inc. (MXCT) in the field of electroporation ensures the stability of this metric; therefore, this rolling annual earnings per share snapshot serves as an objective indicator of fundamental value for the long-term investor.